Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals.
Bc Carleton, Rl Poole, Ma Smith...
https://pubmed.ncbi.nlm.nih.gov/19507171/Actively Recruiting
Led by University of British Columbia · Updated on 2026-05-01
7000
Participants Needed
1
Research Sites
N/A
Total Duration
This research aims to understand how genetic differences affect the way children and adults respond to medications, focusing on those who experience adverse drug reactions ADRs compared to those who do not. The study seeks to identify genetic markers linked to ADRs and to develop personalized drug dosing guidelines to help prevent these reactions. It also examines differences in prescription drug use, medical care, hospital services, and vital statistics between participants with and without ADRs. The study collects DNA and plasma samples from patients who have experienced ADRs and from control groups who have taken the same medications without adverse effects. Researchers analyze known and novel genetic variations related to drug metabolism, transport, and targets, using sequencing and genotyping methods. Pharmacokinetic studies assess drug concentrations over time by genotype to understand ADR mechanisms. The study also includes health-economic evaluations to assess the cost-effectiveness of ADR screening programs. Participants include children under 19 years who have taken drugs, their biological parents, and adults for validation purposes. The study involves collecting genetic and clinical information, medical history, and prescription data. Researchers measure the role of genetic and clinical factors in ADRs to develop risk reduction strategies. Participation involves providing samples and information for analysis, with ongoing data collection to support long-term understanding. The study is observational and includes healthy volunteers, with data collected primarily through hospital networks across Canada.
CONDITIONS
National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children
B
Bruce Carleton, PharmD.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of British Columbia
Lead Sponsor
Genome Canada
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Varies based on participant availability
Participants provide DNA and plasma samples for genetic and pharmacokinetic analyses to identify markers of adverse drug reactions.
1 or more visits depending on sample collection needs
Duration - Up to several years until study completion
Participants are observed over time to evaluate genetic and clinical factors associated with adverse drug reactions.
Follow-up visits as scheduled depending on participant cohort
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Bc Carleton, Rl Poole, Ma Smith...
https://pubmed.ncbi.nlm.nih.gov/19507171/Kheireddin Mufti, Miguel Cordova, Erika N Scott...
https://pubmed.ncbi.nlm.nih.gov/39500896/University of British Columbia
Lead Sponsor
Genome Canada
Collaborating Sponsor